Evgen Pharma (TCF) AI Stock Analysis

• Market Cap: £4.19M
• Dividend Yield: N/A
• Average Volume (3M): 1.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: N/A
• EPS Growth: 85.56%
• Country: UK
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 2,148,963,600
• 10 Day Avg. Volume: 2,190,584
• 30 Day Avg. Volume: 1,685,058
• PEG Ratio: <0.01
• Price to Book (P/B): 0.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): >-0.01
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: 0.19 p ▼(-3.00% Downside)
• Action: Reiterated Date: 02/19/26
• Date: Action: Reiterated 02/19/26

The score is held down primarily by weak fundamentals—ongoing losses, inconsistent revenue, and persistent cash burn—despite recent improvement and a debt-free balance sheet. Technicals are supportive with the price above key moving averages, but overbought RSI reduces the technical score. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.

Positive Factors

Debt-free balance sheet

Having no reported debt materially reduces interest burden and financial leverage for a clinical-stage biotech. This durable strength lowers refinancing risk, improves flexibility to delay dilutive financing, and supports partnership or milestone-led funding strategies over the next 2-6 months.

Negative Factors

Persistent negative operating cash flow

Consistent negative operating and free cash flow means the company cannot self-fund development. Over the medium term this forces reliance on external capital or partner funding, increasing dilution risk and potentially slowing clinical progress if new financing or deals are delayed.

Evgen Pharma Business Overview & Revenue Model

Company Description

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic ...

Read more

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic ...

How the Company Makes Money

Evgen Pharma’s business model is typical of a clinical-stage biotech: it seeks to create value (and ultimately generate revenue) by advancing its drug candidates through clinical development and then monetizing them through partnering and/or comme...

Read more

Evgen Pharma’s business model is typical of a clinical-stage biotech: it seeks to create value (and ultimately generate revenue) by advancing its drug candidates through clinical development and then monetizing them through partnering and/or comme...

Evgen Pharma Financial Statement Overview

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	0.00	0.00	396.00K	442.00K	0.00	194.00K
Gross Profit	-866.00K	-2.11M	385.00K	429.00K	-16.00K	-3.19M
EBITDA	-2.15M	-2.06M	-3.55M	-4.99M	-3.15M	-3.19M
Net Income	-2.01M	-1.94M	-3.14M	-4.04M	-2.73M	-2.67M
Balance Sheet
Total Assets	6.62M	7.63M	3.06M	6.17M	9.64M	12.42M
Cash, Cash Equivalents and Short-Term Investments	3.50M	4.11M	2.00M	5.00M	9.03M	11.59M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.82M	1.66M	721.00K	833.00K	411.00K	607.00K
Stockholders Equity	4.80M	5.97M	2.34M	5.34M	9.23M	11.81M
Cash Flow
Free Cash Flow	-1.68M	-2.37M	-3.00M	-4.03M	-2.56M	-2.93M
Operating Cash Flow	-1.68M	-2.37M	-3.00M	-4.03M	-2.56M	-2.93M
Investing Cash Flow	-1.99M	-2.08M	0.00	4.52M	1.48M	-6.00M
Financing Cash Flow	3.93M	4.55M	0.00	0.00	0.00	10.39M

Evgen Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TCF, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.21, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.73 is Neutral, neither overbought nor oversold. The STOCH value of 64.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TCF.

Evgen Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SCLP	56 Neutral	£124.53M	-4.45	90.29%	―	―	-94.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TCF	49 Neutral	£4.19M	-0.88	-53.79%	―	―	85.56%
HEMO	47 Neutral	£62.04M	-0.27	-3931.14%	―	―	―
IMM	46 Neutral	£29.01M	-3.00	3817.30%	―	―	―
SAR	44 Neutral	£22.09M	-3.13	-202.14%	―	―	23.76%
VAL	41 Neutral	£2.15M	―	―	―	418.49%	27.86%

Evgen Pharma Corporate Events